Iboga interactions with psychomotor stimulants: Panacea in the paradox?

Toxicon

Volumn 39, Issue 1, 2001, Pages 75-86

  Szumlinski, Karen K ^a   Maisonneuve, Isabelle M ^a   Glick, Stanley D ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Cocaine; Dopamine; Drug addiction; Ibogaine; Locomotor activity; Sensitization

Indexed keywords

18 METHOXYCORONARIDINE; AMPHETAMINE; COCAINE; DOPAMINE; IBOGAINE; INDOLE ALKALOID; METHAMPHETAMINE; MORPHINE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COCAINE DEPENDENCE; DOPAMINE BRAIN LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELF ADMINISTRATION; DRUG SENSITIZATION; DRUG STRUCTURE; HUMAN; HYPERACTIVITY; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; STEREOTYPY; TREATMENT OUTCOME;

ANIMALIA; PANACEA;

EID: 0035239221     PISSN: 00410101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-0101(00)00158-6     Document Type: Short Survey

References (68)

1. Angrist B.M., Lee H.K., Gershon S. The antagonism of amphetamine-induced symptomatology by a neuroleptic. American Journal of Psychiatry. 131:1974;817-819.
2. Bardo M.T., Bowling S.L., Pierce R.C. Changes in locomotion and dopamine neurotransmission following amphetamine, haloperidol, and exposure to novel environmental stimuli. Psychopharmacology. 101:1990;338-343.
3. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Research Reviews. 28:1999;309-369.
4. Blackburn J.R., Pfaus J.G., Phillips A.G. Dopamine functions in appetitive and defensive behaviors. Progress in Neurobiology. 39:1992;247-279.
5. Blackburn J.R., Szumlinski K.K. Ibogaine effects on sweet preference and amphetamine-induced locomotion: implications for drug addiction. Behavioral Brain Research. 89:1997;99-106.
6. Cadoni C., Solinas M., Di Chiara G. Psychostimulant sensitization: differential changes in accumbal shell and core dopamine. European Journal of Pharmacology. 388:2000;69-76.
7. Cohen S. Cocaine. The Journal of the American Medical Association. 231:1972;74-75.
8. Creese I., Iversen S.D. Amphetamine response in rat after dopamine neuron destruction. Nature New Biology. 238:1972;247-248.
9. de Wit H. Individual differences in acute effects of drugs in humans: their relevance to risk for abuse. NIDA Research Monographs. 169:1998;176-187.
10. Ellinwood E.H. Jr., Sudilovsky A, Nelson L.M. Evolving behavior in the clinical and experimental amphetamine (model) psychosis. American Journal of Psychiatry, 130:1973;1088-1093.
11. Ellison G. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula. Brain Research Reviews. 19:1994;223-239.
12. Fibiger H.C., Phillips A.G. Reward, motivation, cognition: psychobiology of mesotelencephalic dopamine systems. Mountcastle V.B., Bloom F.E., Geiger S.R. Handbook of Physiology: The Nervous System. 4:1986;647-675 American Physiological Society, Bethesda, MD.
13. Frenken G. From the roots up: ibogaine and addict self-help. Alper K.R., Glick S.D. The Alkaloids. Ibogaine: Proceedings of an Interdisciplinary Conference. 2000;Academic Press, New York. in press.
14. Fuchs R.A., Tran-Nguyen L.T.L., Specio S.E., Groff R.S., Neisewander J.L. Predictive validity of the extinction/reinstatement model of drug craving. Psychopharmacology. 135:1998;151-160.
15. Glick S.D. Changes in amphetamine sensitivity following frontal cortical damage in rats and mice. European Journal of Pharmacology. 20:1972;351-356.
16. Glick S.D., Gallagher C.A., Hough L.B., Rossman K.L., Maisonneuve I.M. Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine. Brain Research. 588:1992;173-176.
17. Glick S.D., Kuehne M.E., Maisonneuve I.M., Bandarage U.K., Molinari H.H. 18-methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Research. 719:1996;29-35.
18. Glick S.D., Kuehne M.E., Raucci J., Wilson T.E., Larson D., Keller R.W. Jr., Carlson J.N. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Research. 657:1994;14-22.
19. Glick S.D., Maisonneuve I.M. Mechanisms of the antiaddictive actions of ibogaine. Annals of the New York Academy of Sciences. 844:1998;214-226.
20. Glick S.D., Maisonneuve I.M., Hough L.B., Kuehne M.E., Bandarage U.K. (±)-18-Methoxycoronaridine: a novel iboga alkaloid congener having potential anti-addictive properties. CNS Drugs. 5:1999;27-42.
21. Glick S.D., Maisonneuve I.M., Szumlinski K.K. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alper K.R., Glick S.D. Ibogaine: Proceedings of an Interdisciplinary Conference. 2000;Academic Press, New York.
22. Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., Carlson J.N. Effects and aftereffects of ibogaine on morphine self-administration in rats. European Journal Pharmacology. 195:1991;341-345.
23. Gold M.S., Bowers M.B. Neurobiological vulnerability to low-dose amphetamine psychosis. American Journal of Psychiatry. 135:1978;1546-1548.
24. Hough L.B., Pearl S.M., Glick S.D. Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration. Life Sciences. 58:1996;PL119-PL122.
25. Ikemoto S., Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Research Reviews. 31:1999;6-41.
26. Jaffe J.H. Drug addiction and drug abuse. Filman A.G., Rall T.W., Nies A.S., Taylor P. The Pharmacological Basis of Therapeutics. 1990;522-573 Pergamon Press, New York.
27. Jongen-Relo A.L., Groenewegen H.J., Voorn P. Evidence for a multi-compartmental histochemical organization of the nucleus accumbens in the rat. The Journal of Comparative Neurology. 337:1993;267-276.
28. Kalivas P.W., Duffy P., DuMars L.A., Skinner C. Behavioral and neurochemical effects of acute and daily cocaine administration in rats. The Journal of Pharmacology and Experimental Therapeutics. 245:1988;485-492.
29. Kalivas P.W., Sorg B.A., Hooks M.S. The pharmacology and neural circuitry of sensitization to psychostimulants. Behavioral Pharmacology. 4:1993;315-334.
30. Kalivas P.W., Pierce R.C., Cornish J., Sorg B.A. A role for sensitization in craving and relapse in cocaine addiction. Journal of Psychopharmacology. 12:1998;49-53.
31. Kalivas P.W., Nakamura M. Neural systems for behavioral activation and reward. Current Opinion in Neurobiology. 9:1999;223-227.
32. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Research Reviews. 16:1991;223-244.
33. Klein M. Research issues related to development of mediations for treatment of cocaine addiction. Annals of the New York Academy of Sciences. 30:1998;75-91.
34. Kreek M.J., Koob G.F. Drug dependence: stress and dysregulation of brain reward pathways. Drug and Alcohol Dependence. 51:1998;23-47.
35. Lieberman J.A., Kinon B.J., Loebel A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophrenia Bulletin 16. 1:1990;97-110.
36. Maisonneuve I.M., Glick S.D. Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior. European Journal of Pharmacology. 212:1992;263-266.
37. Maisonneuve I.M., Glick S.D. Attenuation of the reinforcing efficacy of morphine by 18-methoxycoronaridine. European Journal of Pharmacology. 383:1999;15-21.
38. Maisonneuve I.M., Keller R.W. Jr., Glick S.D. Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. European Journal of Pharmacology. 199:1991;35-42.
39. Maisonneuve I.M., Keller R.W. Jr., Glick S.D. Interactions of ibogaine and d-amphetamine: in vivo microdialysis and motor behavior in rats. Brain Research. 579:1992;87-92.
40. Maisonneuve I.M., Visker K.E., Mann G.L., Bandarage U.K., Kuehne M.E., Glick S.D. Time-dependent interactions between iboga agents and cocaine. European Journal of Pharmacology. 336:1997;123-126.
41. Markou A., Weiss F., Gold L.H., Caine S.B., Schulteis G., Koob G.F. Animal models of drug craving. Psychopharmacology. 112:1993;163-182.
42. Mogenson G.J., Phillips A.G. Motivation: a psychological construct in search of a physiological substrate. Sprague J.M., Epstein A.N. Progress in Psychobiology and Physiological Psychology. 6:1976;189-243 Academic Press, New York.
43. Morgan M.J., Cascella N.G., Stapleton J.M., Phillips R.L., Yung B.C.K., Wong D.F., Shaya E.K., London E.D. Sensitivity to subjective effects of cocaine in drug abusers: relationship to cerebral ventricle size. American Journal of Psychiatry. 150:1993;1712-1717.
44. Pearl S.M., Hough L.B., Boyd D.L., Glick S.D. Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism. Pharmacology, Biochemistry and Behavior. 57:1997;809-815.
45. Pearl S.M., Johnson D.W., Glick S.D. Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation. Psychopharmacology. 121:1995;470-475.
46. Pearl S.M., Maisonneuve I.M., Glick S.D. Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats. Neuropyschopharmacology. 35:1996;1779-1784.
47. Preston K.L., Sullivan J.T., Strain E.C., Bigelow G.E. Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. The Journal of Pharmacology and Experimental Therapeutics. 262:1992;279-291.
48. Rho B., Glick S.D. Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. NeuroReport. 9:1998;1283-1285.
49. Roberts D.C.S. Neural substrates mediating cocaine reinforcement: the role of monoamine systems. Lakoski J.M., Galloway M.P., White F.J. Cocaine: Pharmacology, Physiology, and Clinical Strategies. 1992;73-90 CRC Press, Boca Raton, Florida.
50. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Research Reviews. 396:1986;57-198.
51. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research Reviews. 18:1993;247-291.
52. Segal D.S. Behavioral characterization of d- and l-amphetamine: Neurochemical implications. Science. 190:1975;475-477.
53. Sershen H., Hashim A., Harsing L., Lajtha A. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sciences. 50:1992;1079-1086.
54. Sershen H., Hashim A., Lajtha A. Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacology, Biochemistry and Behavior. 47:1994;13-19.
55. Sheppard S.G. A preliminary investigation of ibogaine: case reports and recommendations for further study. Journal of Substance Abuse Treatment. 11:1994;379-385.
56. Sokolowski J.D., Salamone J.D. The role of accumbens dopamine in lever pressing and response allocation: effects of 6-OHDA injected into core and dorsomedial shell. Pharmacology, Biochemistry and Behavior. 59:1998;557-566.
57. Stewart J., Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behavioral Pharmacology. 4:1993;289-312.
58. Szumlinski, K.K. Balogun, M.Y. Maisonneuve, I.M. Glick, S.D., 2000a. Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats. Psychopharmacology, in press.
59. Szumlinski K.K., Maisonneuve I.M., Glick S.D. Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine. Pharmacology, Biochemistry and Behavior. 63:1999;457-464.
60. Szumlinski K.K., Maisonneuve I.M., Glick S.D. Pretreatment with the putative anti-addictive drug, ibogaine, increases the potency of cocaine to elicit locomotor responding: a study with acute and chronic cocaine-treated rats. Psychopharmacology. 145:1999;227-233.
61. Szumlinski K.K., Maisonneuve I.M., Glick S.D. Iboga agents enhance the expression of cocaine-induced stereotypy in acute and chronic cocaine-treated rats. Behavioral Pharmacology. 10:(1):1999;S92. Suppl.
62. Szumlinski, K.K., Maisonneuve, I.M., Glick, S.D., 2000b. The potential anti-addictive agent, 18-methoxycoronaridine (18-MC) blocks the sensitized dopamine and locomotor responses produced by repeated morphine treatment. Brain Research 864, 13-23.
63. Szumlinski, K.K., Maisonneuve, I.M., Glick, S.D., 2000c. Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine. European Journal of Pharmacology, in press.
64. Szumlinski, K.K., McCafferty, C.A., Maisonneuve, I.M., Glick, S.D., 2000d. Interactions between 18-methoxycoronaridine (18-MC) and cocaine: dissociation of behavioral and neurochemical sensitization. Brain Research, in press.
65. Ujike H., Kanzaki A., Okumura K., Akiyama K., Otsuki S. Sigma ( σ ) antagonist BMY 14802 prevents methamphetamine-induced sensitization. Life Sciences. 50:1992;PL129-PL134.
66. Wei D., Maisonneuve I.M., Kuehne M.E., Glick S.D. Acute iboga effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats. Brain Research. 800:1998;260-268.
67. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychology Reviews. 94:1987;469-492.
68. Wise R.A., Gingras M.A., Amit Z,. Influence of novel and habituated testing conditions on cocaine sensitization. European Journal of Pharmacology. 307:1996;15-19.